// App-Quantinova.ai

POS0930 (2021) : SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: PREDICTORS OF RESPONSE FROM THE DOUBLE-BLIND, RANDOMISED, PHASE 3B MAXIMISE TRIAL

Researchers

Presenter

  • X. Baraliakos

Principal Investigators

  • E. Pournara

  • L. Gossec

  • H. Marzo-Ortega

  • P. J. Mease

  • R. White

  • B. Schulz

  • L. C. Coates

Medical Centers

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

  • Sorbonne Universite, Hopital Pitie-Salpetriere, Paris, France

  • University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

  • Providence St Joseph Health and University of Washington, Swedish Medical Centre, Seattle, United States of America

  • Novartis Ireland Limited, NBS CONEXTS, Dublin, Ireland

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

Locations

  • Germany

  • Switzerland

  • France

  • United Kingdom

  • United States

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

  • Spondyloarthritis

Biomarkers

  • Fas receptor

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved